ZSCAN21
gene geneOn this page
Also known as DKFZp434L134NY-REN-21Zipro1
Summary
ZSCAN21 (zinc finger and SCAN domain containing 21, HGNC:13104) is a protein-coding gene on chromosome 7q22.1, encoding Zinc finger and SCAN domain-containing protein 21 (Q9Y5A6). Strong transcriptional activator.
Enables DNA-binding transcription activator activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Involved in positive regulation of transcription by RNA polymerase II. Predicted to be located in nucleus.
Source: NCBI Gene 7589 — RefSeq curated summary.
At a glance
- GWAS associations: 3
- Clinical variants (ClinVar): 39 total
- MANE Select transcript:
NM_145914
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:13104 |
| Approved symbol | ZSCAN21 |
| Name | zinc finger and SCAN domain containing 21 |
| Location | 7q22.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | DKFZp434L134, NY-REN-21, Zipro1 |
| Ensembl gene | ENSG00000166529 |
| Ensembl biotype | protein_coding |
| OMIM | 601261 |
| Entrez | 7589 |
Gene structure
Transcript identifiers
Ensembl transcripts: 17 — 16 protein_coding, 1 protein_coding_CDS_not_defined
ENST00000292450, ENST00000438937, ENST00000456748, ENST00000477297, ENST00000906173, ENST00000906174, ENST00000906175, ENST00000906176, ENST00000906177, ENST00000906178, ENST00000906179, ENST00000906180, ENST00000938146, ENST00000938147, ENST00000938148, ENST00000938149, ENST00000938150
RefSeq mRNA: 4 — MANE Select: NM_145914
NM_001362779, NM_001362780, NM_001362781, NM_145914
CCDS: CCDS5681, CCDS87526
Canonical transcript exons
ENST00000292450 — 4 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001555916 | 100063788 | 100065040 |
| ENSE00001754262 | 100049774 | 100049841 |
| ENSE00003531656 | 100056911 | 100057405 |
| ENSE00003667730 | 100057698 | 100057890 |
Expression profiles
Bgee: expression breadth ubiquitous, 235 present calls, max score 96.62.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.9157 / max 45.5454, expressed in 1696 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 79916 | 3.0373 | 1548 |
| 79917 | 1.8784 | 1199 |
Top tissues by expression
252 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| oocyte | CL:0000023 | 96.62 | gold quality |
| secondary oocyte | CL:0000655 | 91.91 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 88.96 | gold quality |
| parotid gland | UBERON:0001831 | 87.96 | gold quality |
| cortical plate | UBERON:0005343 | 86.86 | gold quality |
| ventricular zone | UBERON:0003053 | 85.91 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 85.77 | gold quality |
| ganglionic eminence | UBERON:0004023 | 84.72 | gold quality |
| endothelial cell | CL:0000115 | 84.43 | silver quality |
| right uterine tube | UBERON:0001302 | 83.55 | gold quality |
| gastrocnemius | UBERON:0001388 | 83.36 | gold quality |
| muscle of leg | UBERON:0001383 | 83.15 | gold quality |
| kidney epithelium | UBERON:0004819 | 81.99 | silver quality |
| hindlimb stylopod muscle | UBERON:0004252 | 81.92 | gold quality |
| tibialis anterior | UBERON:0001385 | 81.80 | silver quality |
| skeletal muscle organ | UBERON:0014892 | 81.70 | gold quality |
| epithelial cell of pancreas | CL:0000083 | 81.65 | gold quality |
| right lobe of liver | UBERON:0001114 | 81.34 | gold quality |
| deltoid | UBERON:0001476 | 81.13 | silver quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 80.94 | gold quality |
| lower esophagus muscularis layer | UBERON:0035833 | 80.81 | gold quality |
| lower esophagus | UBERON:0013473 | 80.78 | gold quality |
| esophagogastric junction muscularis propria | UBERON:0035841 | 80.26 | gold quality |
| islet of Langerhans | UBERON:0000006 | 79.98 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 79.97 | gold quality |
| adrenal tissue | UBERON:0018303 | 79.93 | gold quality |
| stromal cell of endometrium | CL:0002255 | 79.86 | gold quality |
| calcaneal tendon | UBERON:0003701 | 79.86 | gold quality |
| metanephros | UBERON:0000081 | 79.77 | gold quality |
| granulocyte | CL:0000094 | 79.75 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 3.09 |
Regulation
Is transcription factor: yes
Downstream targets (CollecTRI)
1 targets.
| Target | Regulation |
|---|---|
| SNCA | Unknown |
JASPAR motifs
| Motif | Name | Family |
|---|---|---|
| MA2336.1 | ZSCAN21 | More than 3 adjacent zinc fingers |
JASPAR matrix evidence (PMIDs): PMID:34351703
miRNA regulators (miRDB)
14 targeting ZSCAN21, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-6875-3P | 99.82 | 70.26 | 2983 |
| HSA-MIR-561-3P | 99.64 | 70.90 | 3647 |
| HSA-MIR-6758-3P | 99.57 | 67.55 | 1078 |
| HSA-MIR-3942-3P | 99.57 | 69.03 | 2854 |
| HSA-MIR-6505-3P | 99.34 | 67.39 | 1071 |
| HSA-MIR-10B-3P | 99.04 | 66.98 | 988 |
| HSA-MIR-29B-1-5P | 98.86 | 68.35 | 1364 |
| HSA-MIR-4763-5P | 98.75 | 63.89 | 854 |
| HSA-MIR-4635 | 98.74 | 67.63 | 1339 |
| HSA-MIR-4463 | 98.56 | 66.05 | 1071 |
| HSA-MIR-124-5P | 98.11 | 67.65 | 1095 |
| HSA-MIR-708-3P | 97.50 | 68.67 | 1082 |
| HSA-MIR-5187-3P | 97.28 | 67.10 | 1037 |
| HSA-MIR-4765 | 93.11 | 66.17 | 737 |
Literature-anchored findings (GeneRIF, showing 2)
- This result indicates that NY-REN-21 can function either as a homodimer or as a heterodimer with SCAND1. (PMID:16540086)
- deregulation of the TRIM17/TRIM41/ZSCAN21 pathway may be involved in the pathogenesis of Parkinson’s disease. (PMID:30485814)
Cross-species orthologs
2 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Zscan21 | ENSMUSG00000037017 |
| rattus_norvegicus | Zscan21 | ENSRNOG00000039234 |
Paralogs (30): ZNF263 (ENSG00000006194), ZNF213 (ENSG00000085644), ZNF500 (ENSG00000103199), ZKSCAN1 (ENSG00000106261), ZNF205 (ENSG00000122386), ZSCAN9 (ENSG00000137185), PGBD1 (ENSG00000137338), ZNF215 (ENSG00000149054), ZSCAN12 (ENSG00000158691), ZNF394 (ENSG00000160908), ZNF75A (ENSG00000162086), ZNF232 (ENSG00000167840), ZNF24 (ENSG00000172466), ZNF449 (ENSG00000173275), ZSCAN4 (ENSG00000180532), ZSCAN22 (ENSG00000182318), ZNF75D (ENSG00000186376), ZNF396 (ENSG00000186496), ZNF397 (ENSG00000186812), ZSCAN30 (ENSG00000186814), ZKSCAN4 (ENSG00000187626), ZSCAN23 (ENSG00000187987), ZKSCAN3 (ENSG00000189298), ZSCAN16 (ENSG00000196812), ZSCAN25 (ENSG00000197037), ZSCAN26 (ENSG00000197062), ZNF165 (ENSG00000197279), ZKSCAN8 (ENSG00000198315), ZSCAN31 (ENSG00000235109), ZNF853 (ENSG00000236609)
Protein
Protein identifiers
Zinc finger and SCAN domain-containing protein 21 — Q9Y5A6 (reviewed: Q9Y5A6)
Alternative names: Renal carcinoma antigen NY-REN-21, Zinc finger protein 38 homolog
All UniProt accessions (3): C9JHD9, Q9Y5A6, G3V0F4
UniProt curated annotations — full annotation on UniProt →
Function. Strong transcriptional activator. Plays an important role in spermatogenesis; essential for the progression of meiotic prophase I in spermatocytes.
Subcellular location. Nucleus.
Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.
RefSeq proteins (4): NP_001349708, NP_001349709, NP_001349710, NP_666019* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR003309 | SCAN_dom | Domain |
| IPR013087 | Znf_C2H2_type | Domain |
| IPR036236 | Znf_C2H2_sf | Homologous_superfamily |
| IPR038269 | SCAN_sf | Homologous_superfamily |
Pfam: PF00096, PF02023, PF13465
UniProt features (17 total): zinc finger region 7, cross-link 4, region of interest 2, compositionally biased region 2, chain 1, domain 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9Y5A6-F1 | 66.33 | 0.10 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (4): 27, 221, 232, 349
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 75 (showing top):
GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_MALE_GAMETE_GENERATION, GOBP_ORGANELLE_FISSION, GOBP_MALE_MEIOSIS_I, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, POU3F2_02, GOBP_MEIOTIC_CELL_CYCLE_PROCESS, HU_GENOTOXIC_DAMAGE_4HR, GOBP_MEIOTIC_CELL_CYCLE, SANSOM_APC_TARGETS, GOBP_CELL_CYCLE_PROCESS, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, GOBP_MALE_MEIOTIC_NUCLEAR_DIVISION, FEVR_CTNNB1_TARGETS_UP
GO Biological Process (8): regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357), male meiosis I (GO:0007141), spermatogenesis (GO:0007283), cell differentiation (GO:0030154), positive regulation of transcription by RNA polymerase II (GO:0045944), positive regulation of DNA-templated transcription (GO:0045893), meiotic cell cycle (GO:0051321)
GO Molecular Function (8): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), zinc ion binding (GO:0008270), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872), sequence-specific double-stranded DNA binding (GO:1990837)
GO Cellular Component (1): nucleus (GO:0005634)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| RNA polymerase II transcription regulatory region sequence-specific DNA binding | 3 |
| DNA-templated transcription | 2 |
| regulation of DNA-templated transcription | 2 |
| transcription by RNA polymerase II | 2 |
| male gamete generation | 2 |
| regulation of transcription by RNA polymerase II | 2 |
| regulation of gene expression | 1 |
| regulation of RNA biosynthetic process | 1 |
| meiosis I | 1 |
| male meiotic nuclear division | 1 |
| meiotic cell cycle | 1 |
| developmental process involved in reproduction | 1 |
| cellular developmental process | 1 |
| positive regulation of DNA-templated transcription | 1 |
| positive regulation of RNA biosynthetic process | 1 |
| cell cycle | 1 |
| sexual reproduction | 1 |
| reproductive process | 1 |
| meiotic nuclear division | 1 |
| cis-regulatory region sequence-specific DNA binding | 1 |
| chromatin | 1 |
| DNA-binding transcription factor activity | 1 |
| DNA-binding transcription factor activity, RNA polymerase II-specific | 1 |
| DNA-binding transcription activator activity | 1 |
| positive regulation of transcription by RNA polymerase II | 1 |
| transition metal ion binding | 1 |
| nucleic acid binding | 1 |
| binding | 1 |
| cation binding | 1 |
| double-stranded DNA binding | 1 |
| sequence-specific DNA binding | 1 |
| intracellular membrane-bounded organelle | 1 |
Protein interactions and networks
STRING
704 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| ZSCAN21 | NOX4 | Q9NPH5 | 768 |
| ZSCAN21 | TRIM41 | Q8WV44 | 523 |
| ZSCAN21 | TVP23A | A6NH52 | 430 |
| ZSCAN21 | TRIM17 | Q9Y577 | 415 |
| ZSCAN21 | ZSCAN22 | P10073 | 396 |
| ZSCAN21 | SNCA | P37840 | 376 |
| ZSCAN21 | MPG | P29372 | 350 |
| ZSCAN21 | L3MBTL2 | Q969R5 | 338 |
| ZSCAN21 | RBM14 | Q96PK6 | 329 |
| ZSCAN21 | ZNF219 | Q9P2Y4 | 320 |
| ZSCAN21 | OCEL1 | Q9H607 | 311 |
| ZSCAN21 | BEND3 | Q5T5X7 | 287 |
| ZSCAN21 | FOXP4 | Q8IVH2 | 287 |
| ZSCAN21 | A0A0A6YYI9 | A0A0A6YYI9 | 285 |
| ZSCAN21 | SLC25A39 | Q9BZJ4 | 278 |
IntAct
152 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| CDK8 | MED19 | psi-mi:“MI:2364”(proximity) | 0.850 |
| ZSCAN21 | ZNF24 | psi-mi:“MI:0915”(physical association) | 0.830 |
| ZNF24 | ZSCAN21 | psi-mi:“MI:0915”(physical association) | 0.830 |
| ZSCAN21 | ZNF24 | psi-mi:“MI:0914”(association) | 0.830 |
| GRAP2 | STAMBP | psi-mi:“MI:0914”(association) | 0.810 |
| GRAP2 | ZSCAN21 | psi-mi:“MI:0915”(physical association) | 0.740 |
| ZKSCAN4 | ZSCAN21 | psi-mi:“MI:0915”(physical association) | 0.740 |
| ZSCAN21 | ZNF446 | psi-mi:“MI:0915”(physical association) | 0.720 |
| KRTAP10-8 | ZSCAN21 | psi-mi:“MI:0915”(physical association) | 0.720 |
| ZNF496 | ZSCAN21 | psi-mi:“MI:0915”(physical association) | 0.720 |
| ZSCAN21 | KRTAP10-8 | psi-mi:“MI:0915”(physical association) | 0.720 |
| ZSCAN21 | ZNF496 | psi-mi:“MI:0915”(physical association) | 0.720 |
| ZNF446 | ZSCAN21 | psi-mi:“MI:0915”(physical association) | 0.720 |
| ZSCAN23 | ZSCAN21 | psi-mi:“MI:0915”(physical association) | 0.670 |
| ZNF213 | ZSCAN21 | psi-mi:“MI:0915”(physical association) | 0.670 |
| KRTAP10-5 | ZSCAN21 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZSCAN21 | KRTAP10-9 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZSCAN21 | KRT40 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZSCAN21 | TRIM41 | psi-mi:“MI:0915”(physical association) | 0.560 |
BioGRID (137): ZSCAN21 (Two-hybrid), ZNF446 (Two-hybrid), ZKSCAN7 (Two-hybrid), ZNF496 (Two-hybrid), TRIM41 (Two-hybrid), KRT40 (Two-hybrid), KRTAP10-9 (Two-hybrid), KRTAP10-5 (Two-hybrid), KRTAP10-8 (Two-hybrid), KRTAP10-3 (Two-hybrid), ZSCAN21 (Affinity Capture-MS), ZSCAN21 (Affinity Capture-MS), ZSCAN21 (Affinity Capture-MS), ZSCAN21 (Affinity Capture-MS), ZSCAN21 (Reconstituted Complex)
ESM2 similar proteins: A1YEP8, A1YEV9, A1YFW2, A1YG26, A1YG48, A1YG60, A2T6E3, A2T6V8, A2T712, A2T736, A2T7D2, A2T7F4, A2T7L7, A2T812, A6QNZ0, O14709, O15535, O43296, O43309, P10073, P17023, P17097, P49910, Q07231, Q12901, Q15776, Q16670, Q1LZ87, Q3MJ62, Q53GI3, Q571J5, Q5JNZ3, Q5RAE6, Q5RBX0, Q5RCD9, Q5RJ54, Q7Z7L9, Q86W11, Q8IZ26, Q8NF99
Diamond homologs: A1YEP8, A1YEQ3, A1YEV9, A1YFW2, A1YFW6, A1YG26, A1YG48, A1YG60, A1YGJ4, A1YGK6, A2T6E3, A2T6V8, A2T6W2, A2T712, A2T736, A2T7D2, A2T7D7, A2T7F2, A2T7F4, A2T7L7, A2T812, A6QNZ0, A6QPT6, B2KFW1, O14709, O14771, O14978, O15535, O43309, O60304, O95125, P10073, P17022, P17028, P17029, P17040, P28698, P49910, P51815, P59923
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
39 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 31 |
| Likely benign | 3 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
899 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 7:100057403:CAGG:C | donor_loss | 1.0000 |
| 7:100057406:GT:G | donor_loss | 1.0000 |
| 7:100057693:TCTA:T | acceptor_loss | 1.0000 |
| 7:100057694:CTAG:C | acceptor_loss | 1.0000 |
| 7:100057889:AGGTG:A | donor_loss | 1.0000 |
| 7:100057890:GGTGA:G | donor_loss | 1.0000 |
| 7:100057891:G:GC | donor_loss | 1.0000 |
| 7:100057892:T:G | donor_loss | 1.0000 |
| 7:100049838:CATGG:C | donor_loss | 0.9900 |
| 7:100049883:G:GT | donor_gain | 0.9900 |
| 7:100057406:G:GG | donor_gain | 0.9900 |
| 7:100057696:A:AG | acceptor_gain | 0.9900 |
| 7:100057697:G:GG | acceptor_gain | 0.9900 |
| 7:100052077:A:AG | donor_gain | 0.9800 |
| 7:100057697:GGT:G | acceptor_gain | 0.9800 |
| 7:100057697:GGTC:G | acceptor_gain | 0.9800 |
| 7:100057697:GGTCT:G | acceptor_gain | 0.9800 |
| 7:100058140:AAAG:A | acceptor_gain | 0.9800 |
| 7:100063786:A:AG | acceptor_gain | 0.9800 |
| 7:100063787:G:GG | acceptor_gain | 0.9800 |
| 7:100063787:GA:G | acceptor_gain | 0.9800 |
| 7:100049842:G:GG | donor_gain | 0.9700 |
| 7:100049879:A:T | donor_gain | 0.9700 |
| 7:100052077:A:G | donor_gain | 0.9700 |
| 7:100057696:AG:A | acceptor_gain | 0.9700 |
| 7:100057697:GG:G | acceptor_gain | 0.9700 |
| 7:100057891:G:GG | donor_gain | 0.9700 |
| 7:100063783:TTCAG:T | acceptor_loss | 0.9700 |
| 7:100063785:CA:C | acceptor_loss | 0.9700 |
| 7:100049844:GA:G | donor_loss | 0.9600 |
AlphaMissense
3129 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 7:100064051:T:C | F286L | 1.000 |
| 7:100064053:T:A | F286L | 1.000 |
| 7:100064053:T:G | F286L | 1.000 |
| 7:100064135:T:C | F314L | 1.000 |
| 7:100064137:C:A | F314L | 1.000 |
| 7:100064137:C:G | F314L | 1.000 |
| 7:100064216:T:C | F341L | 1.000 |
| 7:100064218:T:A | F341L | 1.000 |
| 7:100064218:T:G | F341L | 1.000 |
| 7:100064300:T:C | F369L | 1.000 |
| 7:100064302:C:A | F369L | 1.000 |
| 7:100064302:C:G | F369L | 1.000 |
| 7:100064384:T:C | F397L | 1.000 |
| 7:100064386:C:A | F397L | 1.000 |
| 7:100064386:C:G | F397L | 1.000 |
| 7:100064468:T:C | F425L | 1.000 |
| 7:100064470:C:A | F425L | 1.000 |
| 7:100064470:C:G | F425L | 1.000 |
| 7:100064552:T:C | F453L | 1.000 |
| 7:100064554:C:A | F453L | 1.000 |
| 7:100064554:C:G | F453L | 1.000 |
| 7:100064052:T:C | F286S | 0.999 |
| 7:100064070:T:C | L292P | 0.999 |
| 7:100064078:C:G | H295D | 0.999 |
| 7:100064080:C:A | H295Q | 0.999 |
| 7:100064080:C:G | H295Q | 0.999 |
| 7:100064092:C:A | H299Q | 0.999 |
| 7:100064092:C:G | H299Q | 0.999 |
| 7:100064114:T:C | C307R | 0.999 |
| 7:100064135:T:A | F314I | 0.999 |
dbSNP variants (sampled 300 via entrez): RS1000174343 (7:100060508 G>A,C), RS1000547772 (7:100058223 G>A), RS1000637003 (7:100052921 G>A), RS1000798357 (7:100052790 G>A), RS1000911406 (7:100059165 G>C), RS1001301328 (7:100063652 T>C), RS1001500607 (7:100059376 T>C), RS1001587981 (7:100054044 C>T), RS1001640159 (7:100054395 G>A), RS1001802515 (7:100048232 G>A), RS1002358320 (7:100051193 A>T), RS1002410635 (7:100050850 T>C), RS1002593950 (7:100055776 A>T), RS1002594911 (7:100056430 G>A,C), RS1002644932 (7:100056182 G>A,C)
Disease associations
OMIM: gene MIM:601261 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
3 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST010002_259 | Refractive error | 3.000000e-16 |
| GCST010702_48 | Subcortical volume (MOSTest) | 6.000000e-10 |
| GCST010703_289 | Brain morphology (MOSTest) | 6.000000e-15 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004346 | neuroimaging measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
30 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide | decreases expression | 1 |
| TAK-243 | increases sumoylation | 1 |
| triphenyl phosphate | affects expression | 1 |
| bisphenol A | affects cotreatment, increases expression | 1 |
| trichostatin A | affects expression | 1 |
| perfluorooctanoic acid | decreases expression | 1 |
| manganese chloride | increases abundance, increases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| perfluorooctane sulfonic acid | decreases expression | 1 |
| perfluoro-n-nonanoic acid | decreases expression | 1 |
| perfluorohexanesulfonic acid | decreases expression | 1 |
| abrine | increases expression | 1 |
| 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide | affects cotreatment, decreases expression | 1 |
| Leflunomide | increases expression | 1 |
| Vehicle Emissions | increases expression, increases abundance | 1 |
| Benzo(a)pyrene | increases methylation | 1 |
| Dexamethasone | affects cotreatment, increases expression | 1 |
| Ethyl Methanesulfonate | increases expression | 1 |
| Formaldehyde | increases expression | 1 |
| Indomethacin | affects cotreatment, increases expression | 1 |
| Manganese | increases abundance, increases expression | 1 |
| Methyl Methanesulfonate | increases expression | 1 |
| Quercetin | increases expression | 1 |
| Tetrachlorodibenzodioxin | decreases expression, affects cotreatment | 1 |
| Valproic Acid | affects expression | 1 |
| 1-Methyl-3-isobutylxanthine | affects cotreatment, increases expression | 1 |
| Cadmium Chloride | decreases expression | 1 |
| Copper Sulfate | decreases expression | 1 |
| Acrylamide | increases expression | 1 |
| Particulate Matter | increases abundance, increases expression | 1 |
Cellosaurus cell lines
1 cell lines: 1 transformed cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_XW92 | HEK293 eGFP-ZSCAN21 | Transformed cell line | Female |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.